Bogart Wealth LLC Sells 82 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bogart Wealth LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73 shares of the medical research company’s stock after selling 82 shares during the period. Bogart Wealth LLC’s holdings in Thermo Fisher Scientific were worth $38,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mcrae Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Mcrae Capital Management Inc. now owns 27,769 shares of the medical research company’s stock valued at $14,447,000 after purchasing an additional 2,080 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Asset Management One Co. Ltd. now owns 181,829 shares of the medical research company’s stock valued at $95,655,000 after purchasing an additional 2,284 shares during the last quarter. Avestar Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 18.4% in the 4th quarter. Avestar Capital LLC now owns 3,788 shares of the medical research company’s stock valued at $1,971,000 after purchasing an additional 590 shares during the last quarter. Sawgrass Asset Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.4% in the 4th quarter. Sawgrass Asset Management LLC now owns 4,040 shares of the medical research company’s stock valued at $2,102,000 after purchasing an additional 96 shares during the last quarter. Finally, Phraction Management LLC lifted its stake in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Phraction Management LLC now owns 28,127 shares of the medical research company’s stock valued at $14,633,000 after purchasing an additional 527 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock worth $11,231,699 in the last ninety days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 0.0 %

Shares of NYSE:TMO opened at $532.58 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The business’s fifty day simple moving average is $548.51 and its 200-day simple moving average is $570.52. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $203.71 billion, a PE ratio of 32.22, a P/E/G ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. TD Cowen raised their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. UBS Group raised their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Stifel Nicolaus decreased their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Finally, Barclays decreased their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.